Menu
Menu
SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.
More information is coming soon!
SOPHiA GENETICS is heading to the European Society for Medical Oncology Congress (ESMO) 2026 in Madrid, Spain. Meet our team at Booth #8068 to learn how we are helping advance precision medicine through intelligent analytics and collaborative innovation.
More updates on our participation and activities will be announced soon!
Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. We are excited to engage with the pathology community and share how our technology helps transform complex data into practical insights.
Visit our page again shortly for more information!
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions.
Additional details will be available soon!
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
Join SOPHiA GENETICS at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden! Our team of experts will be at Booth #214 to engage with partners and peers across the genomics community.
Stay tuned for information and session updates!
The future of precision medicine is coming to San Sebastián!
The EMEA Innovation Summit by SOPHiA GENETICS explores how precision medicine is scaling today, and what breakthroughs will shape clinical care tomorrow.
Following the success of our 2025 edition in Rolle, we’re thrilled to host the next SOPHiA GENETICS Innovation Summit at the iconic Real Sociedad Arena, a venue that captures the energy, innovation, and collaboration that define our community.
This year’s agenda is set to dive deep into innovation, from AI-driven discovery and liquid biopsy advancements to collaborative approaches in oncology and clinical genomics. Expect thought-provoking sessions, impactful discussions, and cross-industry networking designed to accelerate innovation in healthcare.
Over two days, the event brings together:
Together, we connect insights with real-world impact bridging today’s scalable platforms with tomorrow’s clinical breakthroughs.
The day will begin with a focus on scalability and operational maturity, tackling the growing challenges of data volume and complexity while building robust end-to-end workflows. Through AI-driven insights, we’ll explore how to accelerate the global adoption of precision medicine. In the afternoon, the spotlight shifts to future-facing clinical innovation, diving into next-generation data modalities and their applications across solid tumors, liquid biopsy, blood cancers, and germline analysis. Bringing it all together, the sessions highlight real-world clinical studies, emerging technologies, and pharma perspectives, showcasing how advanced analytics are translating into meaningful clinical impact.
Fill out the form to secure your spot!
Do you have any questions or require further assistance? Please get in touch with us!
We’re pleased to welcome AZ Delta Roeselare in Belgium, one of the largest hospitals in Flanders, to the SOPHiA GENETICS community as they expand their precision medicine capabilities by adopting a broad range of applications on the SOPHiA DDM™ Platform.
Through this adoption, AZ Delta Roeselare is advancing data-driven medicine across both blood and solid tumor indications, leveraging germline and somatic solutions across SOPHiA DDM™ to support insights into complex diseases. By consolidating diverse genomic workflows within a single platform, the hospital is strengthening multidisciplinary collaboration and streamlining the analysis of complex genomic data across multiple indications.
We’re proud to support their work as part of the SOPHiA GENETICS community.
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our leadership team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine
The SOPHiA GENETICS team is thrilled to see you at our Fireside chat on Monday, May 4th from 15.30 to 16.15, in Room Delhi – Level 0.
“Liquid Biopsy at a Tipping Point in Precision Oncology”
Join Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS, Elena Guerini Rocco, MD, Director of the Oncology Genetics Unit, IEO – Istituto Europeo di Oncologia, and Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca for an insightful conversation about the liquid biopsy movement.
We are thrilled to be back at 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
The SOPHiA GENETICS team is looking forward to seeing you join our Pre-Conference Workshop Day and Plenary Talk.
Pre-Conference Workshop Day on Monday, March 30th, from 2.30 to 4.30 pm.
“Pioneering Precision Medicine: A New Model for CDx Development and Commercialization”
In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.
This is an invitation-only workshop session. If you are interested in attending, please fill out our Engager Form
Plenary talk on Tuesday, March 31st, from 12.00 to 12.30 pm.
“Establishing a Scalable Liquid Biopsy Strategy: Foundations of a Global CDx Ecosystem”
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.